Senores Pharmaceuticals has announced the availability of the audio recording from its Earnings Conference Call held on Monday, July 27, 2026, pertaining to the company's unaudited financial results for the quarter ended June 30, 2026. The call was conducted with several analysts, institutional investors, funds, and other investors, in accordance with Regulations 30 and 46 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Earnings Call Details

The following key details pertain to the Earnings Conference Call conducted by Senores Pharmaceuticals:

Regulatory Compliance

The disclosure was made in compliance with SEBI's listing regulations, and the company has confirmed that no Unpublished Price Sensitive Information (UPSI) was shared or discussed during the Earnings Conference Call. The filing was signed by Deval Rajnikant Shah, Whole Time Director & CFO (DIN: 00332722), on July 27, 2026.

Access to Recording

Investors and other stakeholders can access the audio recording of the Earnings Conference Call through the company's investor relations page at https://senorespharma.com/investor-meet/ . The recording has been made available as part of the company's ongoing commitment to transparency and regulatory compliance under applicable SEBI listing norms.

Senores Pharmaceuticals reported a consolidated net profit of ₹31 crore for the quarter ended June 30, 2026 (Q1FY27), marking a 56% year-on-year increase from the previous period. The Ahmedabad-based pharmaceutical company also posted a 36% surge in consolidated revenue from operations, reaching ₹180 crore against ₹132.6 crore in Q1FY26. This robust performance underscores the strength of its Regulated Markets segment, which contributed significantly to the top-line growth, alongside steady expansion in Emerging Markets.

The Board of Directors approved the unaudited financial results on July 27, 2026. The limited review report was issued by statutory auditors Pankaj R. Shah and Associates. The Board also approved the categorization of Ms. Anjali Shah, Assistant Vice President-Finance, as Senior Management Personnel effective July 27, 2026, pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Financial Performance

Consolidated EBITDA for the quarter stood at ₹54 crore, reflecting an 87% year-on-year growth and an expansion of approximately 800 basis points in margins. The profit before tax was ₹39.46 crore, compared to ₹26.49 crore in Q1FY26. Other income declined to ₹2.81 crore from ₹8.79 crore in the prior year quarter, primarily due to lower one-time gains, though operational profitability remained strong.

*Note: EBITDA for Q1FY26 derived from disclosed growth rate and current EBITDA. **Note: Prior year PAT derived from disclosed growth rate and current PAT.

On a standalone basis, the parent company reported a net profit of ₹1.03 crore, down from ₹2.70 crore in Q1FY26. Standalone revenue from operations was ₹26.99 crore, up from ₹16.13 crore in the previous year. The divergence between consolidated and standalone results highlights the significant contribution of subsidiaries, particularly in international markets.

Segmental Highlights

The Regulated Markets business, comprising the US and Canada, remained the primary growth driver. Revenue from this segment reached ₹127.8 crore, up 42% from ₹90.1 crore in Q1FY26. The Emerging Markets segment also showed steady growth, with revenue rising 30% to ₹37.6 crore from ₹29.0 crore. Branded Generics revenue contracted slightly by 2.4% to ₹8.0 crore. Swapnil Shah, Managing Director, attributed the performance to the expansion of the product portfolio, which has nearly doubled from 30 ANDAs as of June 2025 to 58 approved ANDAs as of June 2026. Of these, 23 have been commercialized.

Regulated Markets contributed 71% of total revenue in Q1FY27, with an EBITDA margin of approximately 40%. Emerging Markets contributed 21% of total revenue, with an EBITDA margin of approximately 14%. The CDMO/CMO business, focused on specialty, government supplies, and controlled substances, saw its commercialized products grow from 27 to 34, while pipeline products increased from 15 to 16.

IPO Fund Utilization

As of June 30, 2026, Senores Pharmaceuticals had utilized ₹399.5 crore out of the ₹500 crore raised through its IPO. The unutilized amount stood at ₹100.5 crore. Key utilization areas included:

• Repayment of borrowings: ₹73.1 crore fully utilized.
• Investment in subsidiary Havix for borrowing repayment: ₹20.2 crore fully utilized.
• Working capital requirements: ₹43.26 crore utilized against ₹43.3 crore proposed.
• Inorganic growth and strategic initiatives: ₹161.63 crore utilized against ₹161.9 crore proposed.
• Offer expenses: ₹34.8 crore utilized against ₹35.0 crore proposed.

Only ₹6.98 crore was utilized towards the investment in Havix for setting up a manufacturing facility for sterile injections in Atlanta, leaving ₹100.0 crore unutilized for this specific purpose.

What the Numbers Show

The significant disparity between standalone and consolidated profitability indicates that Senores Pharmaceuticals’ value creation is increasingly dependent on its international subsidiaries. While the Indian entity reported modest standalone profits of ₹1.03 crore, the group delivered ₹31 crore in net profit, driven largely by the high-margin Regulated Markets segment. Furthermore, the sharp decline in other income did not dampen overall profit growth, suggesting that core operational efficiency improvements—evidenced by the 800-basis-point margin expansion—are sustainable drivers rather than one-off financial gains. The Emerging Markets business is now cash flow positive with an EBITDA margin of approximately 14%.

Source: https://lodr-files.dhan.co/lodr-inputs/Company/INE0RB801010/ba9a9c76-b76b-4b4f-a98b-6f2555381ebf.pdf